BUSINESS BITES: Tissue Regenix Sets Up JV For Heart Valve, Skin Graft Sales; bioTheranostics Stands On Its Own; Hello Trividia
This article was originally published in Clinica
Executive Summary
UK regenerative medicine specialist Tissue Regenix (TRX) is setting up a joint venture in Germany with Rostock-based tissue bank GTM-V to commercialize its dCell replacement heart valves and DermaPure skin graft products in Europe. The products are manufactured using TRX’s dCell technology for decellularizing tissue. DermaPure is already sold in over 30 states the US but is not yet available in the EU. The joint venture, called GBM-V, will prepare regulatory submissions to the German authorities to obtain the required approvals for the products. The first products are targeted to be launched in 2017. “Germany is particularly stringent with its human tissue regulations, which provides a high benchmark from which wider EU approvals can follow,” said Antony Odell, CEO of TRX. Odell and Frank Peter Nitschke will be joint CEOs of GBM-V.